BAF312 + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Active Dermatomyositis
Conditions
Active Dermatomyositis
Trial Timeline
Aug 25, 2013 → Feb 17, 2016
NCT ID
NCT02029274About BAF312 + Placebo
BAF312 + Placebo is a phase 2 stage product being developed by Novartis for Active Dermatomyositis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02029274. Target conditions include Active Dermatomyositis.
What happened to similar drugs?
20 of 20 similar drugs in Active Dermatomyositis were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02029274 | Phase 2 | Terminated |
| NCT01665144 | Phase 3 | Completed |
| NCT01148810 | Phase 2 | Terminated |
| NCT00879658 | Phase 2 | Completed |
Competing Products
20 competing products in Active Dermatomyositis